Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.52 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.52 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679326 | 0.90 | ALDH1A1 (0.67) | HPGDALDH1A1TSHRSMN1; SMN2HSD11B1 | |
| SCHEMBL26047844 | 0.86 | HPGD (0.43) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24026631 | 0.82 | HPGD (0.43) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL29607150 | 0.80 | ALDH1A1 (0.48) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL2956853 | 0.78 | — | — | |
| SCHEMBL19569940 | 0.78 | ALDH1A1 (0.75) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL453485 | 0.77 | — | — | |
| SCHEMBL31708220 | 0.76 | HTT (0.37) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25498349 | 0.76 | HTT (0.44) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL21577629 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | HPGD 43/4885CHRNB2 3048/4885CHRNA3 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.